These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6381432)

  • 61. [Chemical modifiers in radiotherapy].
    Nagashima T; Takakura K
    Gan No Rinsho; 1989 Sep; 35(11):1369-71. PubMed ID: 2681875
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [The use of radiosensitizing agents in radiotherapy].
    Franke HD
    Fortschr Geb Rontgenstr Nuklearmed; 1972; ():Suppl:199-201. PubMed ID: 4115508
    [No Abstract]   [Full Text] [Related]  

  • 63. Mucocutaneous complications of intraarterial 5-bromodeoxyuridine and radiation.
    McCuaig CC; Ellis CN; Greenberg HS; Hegarty TJ; Page MA
    J Am Acad Dermatol; 1989 Dec; 21(6):1235-40. PubMed ID: 2584461
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Halogenated pyrimidines as radiosensitizers for high-LET radiation.
    Atcher RW; Russo A; DeGraff WG; Moore M; Grdina DJ; Mitchell JB
    Radiat Res; 1989 Feb; 117(2):351-5. PubMed ID: 2922478
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mechanism of radiosensitization by halogenated pyrimidines: bromodeoxyuridine and beta-arabinofuranosyladenine affect similar subsets of radiation-induced potentially lethal lesions in plateau-phase Chinese hamster ovary cells.
    Iliakis G; Kurtzman S
    Radiat Res; 1991 Jul; 127(1):45-51. PubMed ID: 2068271
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure.
    Lawrence TS; Davis MA; Maybaum J; Stetson PL; Ensminger WD
    Int J Radiat Oncol Biol Phys; 1990 Jun; 18(6):1393-8. PubMed ID: 2370189
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Continuous infusion of halogenated pyrimidines.
    Rodriguez R; Miller E; Fowler JF; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 1991 Jun; 20(6):1380-2. PubMed ID: 2045313
    [No Abstract]   [Full Text] [Related]  

  • 68. Auger electron contribution to bromodeoxyuridine cellular radiosensitization.
    Larson D; Bodell WJ; Ling C; Phillips TL; Schell M; Shrieve D; Troxel T
    Int J Radiat Oncol Biol Phys; 1989 Jan; 16(1):171-6. PubMed ID: 2912939
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Association of taxanes and radiotherapy: preclinical and clinical studies].
    Hennequin C
    Cancer Radiother; 2004 Nov; 8 Suppl 1():S95-105. PubMed ID: 15679254
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
    Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
    Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. II. Radiosensitization of human colon cancer cells by bromodeoxyuridine.
    Miller EM; Fowler JF; Kinsella TJ
    Radiat Res; 1992 Jul; 131(1):90-7. PubMed ID: 1626053
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
    Prados MD; Scott C; Sandler H; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1109-15. PubMed ID: 10613302
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Radiation enhancement with iodinated deoxyuridine.
    Fairchild RG; Brill AB; Ettinger KV
    Invest Radiol; 1982; 17(4):407-16. PubMed ID: 6813285
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Taxanes in combined-modality therapy for solid tumors.
    Choy H
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):23-38. PubMed ID: 10550824
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Iododeoxyuridine incorporation and radiosensitization in three human tumor cell lines.
    Uhl V; Phillips TL; Ross GY; Bodell WJ; Rasmussen J
    Int J Radiat Oncol Biol Phys; 1992; 22(3):489-94. PubMed ID: 1735685
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by iododeoxyuridine.
    Miller EM; Fowler JF; Kinsella TJ
    Radiat Res; 1992 Jul; 131(1):81-9. PubMed ID: 1626052
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by beta-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran- 5,6-dione), a novel DNA repair inhibitor.
    Boothman DA; Greer S; Pardee AB
    Cancer Res; 1987 Oct; 47(20):5361-6. PubMed ID: 3652040
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunohistochemical double staining with immunogold-silver and alkaline phosphatase to identify nuclear markers of cellular proliferation.
    Shibuya M; Ito S; Davis RL; Hoshino T
    Biotech Histochem; 1993 Jan; 68(1):17-9. PubMed ID: 8383543
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Genetics of human cell lines. III. Incorporation of 5-bromo- and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells and its effect on radiation sensitivity.
    DJORDJEVIC B; SZYBALSKI W
    J Exp Med; 1960 Sep; 112(3):509-31. PubMed ID: 13723177
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Taxol plus radiation for head and neck cancer.
    Rosenthal DI; Carbone DP
    J Infus Chemother; 1995; 5(2):46-54. PubMed ID: 8521234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.